TY - JOUR. T1 - International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. AU - Terpos, Evangelos. AU - Morgan, Gareth. AU - Dimopoulos, Meletios A.. AU - Drake, Matthew T.. AU - Lentzsch, Suzanne. AU - Raje, Noopur. AU - Sezer, Orhan. AU - García-Sanz, Ramón. AU - Shimizu, Kazuyuki. AU - Turesson, Ingemar. AU - Reiman, Tony. AU - Jurczyszyn, Artur. AU - Merlini, Giampaolo. AU - Spencer, Andrew. AU - Leleu, Xavier. AU - Cavo, Michele. AU - Munshi, Nikhil. AU - Rajkumar, S. Vincent. AU - Durie, Brian G.M.. AU - Roodman, G. David. N1 - Publisher Copyright: © 2013 by American Society of Clinical Oncology. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.. PY - 2013/6/20. Y1 - 2013/6/20. N2 - Purpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. Methodology An interdisciplinary panel of clinical experts on MM and myeloma ...
25.1. Introduction. 25.2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 25.2.1. Definition of multiple myeloma. 25.2.2. Definition of smouldering multiple myeloma. 25.2.3. Definition of monoclonal gammopathy of undetermined significance. 25.3. International Myeloma Working Group guidelines. 25.3.1. Guidelines for serum free light chain analysis in multiple myeloma and related disorders (2009). 25.3.2. Guidelines for monoclonal gammopathy of undetermined significance and smouldering multiple myeloma (2010). 25.3.3. Guidelines for standard investigative work-up of patients with suspected multiple myeloma (2011). 25.3.4. Guidelines for risk stratification in multiple myeloma (2011). 25.3.5. Consensus criteria for response and minimal residual disease assessment in multiple myeloma (2016). 25.3.6. Recommendations for global myeloma care (2013). 25.3.7. Recommendations for the diagnosis and management of myeloma-related renal impairment (2016). 25.4. ...
The latest market report published by Credence Research, Inc. Global Multiple Myeloma Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025, the Multiple Myeloma Treatment market was valued at USD 8,398.3 Mn in 2016, and is expected to reach USD 21,221.8 Mn by 2025, expanding at a CAGR of 11.0% from 2017 to 2025.. Browse the full report Multiple Myeloma Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025 at http://www.credenceresearch.com/report/multiple-myeloma-treatment-market. Market Insights. Multiple myeloma treatment options have developed significantly over the last decade. Novel multiple myeloma treatments have provided efficient survival rates among myeloma patients. It has been also observed that the upcoming drug pipeline of multiple myeloma is promising, biological drugs and stem cell based therapies are expected to drive the market in the near future. The key players operating in this industry ...
25.1. Introduction. 25.2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 25.2.1. Definition of multiple myeloma. 25.2.2. Definition of smouldering multiple myeloma. 25.2.3. Definition of monoclonal gammopathy of undetermined significance. 25.3. International Myeloma Working Group guidelines. 25.3.1. Guidelines for serum free light chain analysis in multiple myeloma and related disorders (2009). 25.3.2. Guidelines for monoclonal gammopathy of undetermined significance and smouldering multiple myeloma (2010). 25.3.3. Guidelines for standard investigative work-up of patients with suspected multiple myeloma (2011). 25.3.4. Guidelines for risk stratification in multiple myeloma (2011). 25.3.5. Consensus criteria for response and minimal residual disease assessment in multiple myeloma (2016). 25.3.6. Recommendations for global myeloma care (2013). 25.3.7. Recommendations for the diagnosis and management of myeloma-related renal impairment (2016). 25.4. ...
To investigate the patterns of genetic lesions in a panel of 23 human multiple myeloma cell lines (HMCLs), we made a genomic integrative analysis involving FISH, and both gene expression and genome-wide profiling approaches. The expression profiles of the genes targeted by the main IGH translocations showed that the WHSC1/MMSET gene involved in t(4;14)(p16;q32) was expressed at different levels in all of the HMCLs, and that the expression of the MAF gene was not restricted to the HMCLs carrying t(14;16)(q32;q23). Supervised analyses identified a limited number of genes specifically associated with t(4;14) and involved in different biological processes. The signature related to MAF/MAFB expression included the known MAF target genes CCND2 and ITGB7, as well as genes controlling cell shape and cell adhesion. Genome-wide DNA profiling allowed the identification of a gain on chromosome arm 1q in 88% of the analyzed cell lines, together with recurrent gains on 8q, 18q, 7q, and 20q; the most frequent ...
43 NCCN Guidelines for Patients ® : Multiple Myeloma, 2018 4 Treatment guide Active (symptomatic) multiple myeloma Active (symptomatic) multiple myeloma Guide 5 shows the primary treatment options for multiple myeloma that is causing symptoms and follow-up tests. Myeloma that is causing symptoms is called active myeloma or symptomatic myeloma. Primary treatment is the first treatment given to try to rid your body of cancer. Primary treatment for active myeloma includes systemic therapies. Systemic therapy travels in your body to treat more than one area of cancer. This type of treatment includes chemotherapy, targeted therapy, and steroids. These drugs may be given alone or in combination. Follow-up tests are usually done after 1 to 2 cycles of treatment to see whether or not the treatment is working or if the disease is progressing (getting worse). Treatment for active myeloma may or may not include a stem cell transplant. A stem cell transplant is not a good treatment option for everyone. ...
TY - JOUR. T1 - Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. AU - Nguyen, Aaron N.. AU - Stebbins, Elizabeth G.. AU - Henson, Margaret. AU - OYoung, Gilbert. AU - Choi, Sun J.. AU - Quon, Diana. AU - Damm, Debby. AU - Reddy, Mamatha. AU - Ma, Jing Y.. AU - Haghnazari, Edwin. AU - Kapoun, Ann M.. AU - Medicherla, Satyanarayana. AU - Protter, Andy. AU - Schreiner, George F.. AU - Kurihara, Noriyoshi. AU - Anderson, Judy. AU - Roodman, G. David. AU - Navas, Tony A.. AU - Higgins, Linda S.. PY - 2006/6/10. Y1 - 2006/6/10. N2 - The multiple myeloma (MM) bone marrow (BM) microenvironment plays a critical role in supporting tumor growth and survival as well as in promoting formation of osteolytic lesions. Recent results suggest that the p38 mitogen-activated protein kinase (MAPK) is an important factor in maintaining this activated environment. In this report, we demonstrate that the p38α ...
The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi. The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma. Patients with relapsed or refractory multiple myeloma treated with Kyprolis® and dexamethasone lived 7.6 months longer than those treated with Velcade® and dexamethasone.1. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the bodys immune system. In the U.S., approximately 70,000 people are living with multiple myeloma and approximately 24,000 new individuals are diagnosed annually. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or ...
PubMed journal article: Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal. Download Prime PubMed App to iPhone, iPad, or Android
References. 1. Centre for Evidence Based Medicine [Internet]. Oxford: University of Oxford; 2011. [cited 2012 Nov 21]. Available from: http:// www.cebm.net. [ Links ] 2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60. Comment in: N Engl J Med. 2011;364(24):2364; author reply 2364. [ Links ] 3. Hungria VT, Maiolino A, Martinez G, Colleoni GW, Coelho EO, Rocha L, Nunes R, Bittencourt R, Oliveira LC, Faria RM, Pasquini R, Magalhães SM, Souza CA, Pinto Neto JV, Barreto L, Andrade E, Portella M do S, Bolejack V, Durie BG; International Myeloma Working Group Latin America. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica 2008;93(5):791-2. [ Links ] 4. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment ...
TY - JOUR. T1 - Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. AU - Opperman, Khatora S.. AU - Vandyke, Kate. AU - Clark, Kimberley C.. AU - Coulter, Elizabeth A.. AU - Hewett, Duncan R.. AU - Mrozik, Krzysztof M.. AU - Schwarz, Nisha. AU - Evdokiou, Andreas. AU - Croucher, Peter I.. AU - Psaltis, Peter. AU - Noll, Jacqueline E.. AU - Zannettino, Andrew. PY - 2019/8/1. Y1 - 2019/8/1. N2 - Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment. The bone marrow is comprised of numerous cells of mesenchymal and hemopoietic origin. Of these, macrophages have been implicated to play a role in myeloma disease progression, angiogenesis, and drug resistance; however, the role of macrophages in myeloma disease establishment remains unknown. In this study, the antimyeloma efficacy of clodronate-liposome treatment, which globally and transiently depletes macrophages, was evaluated in the ...
Multiple myeloma is a haematological malignancy characterized by the clonal proliferation of plasma cells. It has been proposed that targeting cancer cell metabolism would provide a new selective anticancer therapeutic strategy. In this work, we tested the hypothesis that inhibition of β-oxidation and de novo fatty acid synthesis would reduce cell proliferation in human myeloma cells. We evaluated the effect of etomoxir and orlistat on fatty acid metabolism, glucose metabolism, cell cycle distribution, proliferation, cell death and expression of G1/S phase regulatory proteins in myeloma cells. Etomoxir and orlistat inhibited β-oxidation and de novo fatty acid synthesis respectively in myeloma cells, without altering significantly glucose metabolism. These effects were associated with reduced cell viability and cell cycle arrest in G0/G1. Specifically, etomoxir and orlistat reduced by 40-70% myeloma cells proliferation. The combination of etomoxir and orlistat resulted in an additive inhibitory effect
Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma cell growth and resistance to conventional therapies. Although multiple myeloma remains incurable, novel targeted agents, used alo …
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029 report has been added to ResearchAndMarkets.coms offering. This report offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration 2019 to 2029. The said research study cover in-depth analysis of multiple myeloma market segments based on type and different geographies further segmented by countries. According to myeloma UK, in myeloma, plasma cells become abnormal, multiply uncontrollably and release only one type of antibody known as paraprotein, which has no useful function. It is often through the measurement of this paraprotein that myeloma is diagnosed and monitored.For the purpose of this study, the global multiple myeloma treatment market is segmented on the basis of type into Drug Therapy, Stem cell
Many clinical studies for the treatment of multiple myeloma have been conducted in Korea, but none of them have evaluated the improvement in the quality of life in patients with multiple myeloma. Most study variables used to evaluate the quality of life of patients with multiple myeloma are subjective and limited. This study will observe the degree of change in the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions), validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma.. Observational Study - No investigational drug ...
Celgene Corp. (CELG) announced Friday that the U.S. Food and Drug Administration or FDA has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Background: Elderly patients with multiple myeloma are a challenging population to treat, and there is a need for effective treatment options. Carfilzomib, a selective proteasome inhibitor, is approved in the United States and other countries for the treatment of relapsed or refractory multiple myeloma (RRMM). A subgroup analysis of interim results from the randomized, phase 3 ENDEAVOR study showed that carfilzomib (56 mg/m2) and dexamethasone (Kd56) resulted in longer median progression-free survival (PFS) and higher overall response rates (ORRs) than bortezomib and dexamethasone (Vd) in patients with RRMM, regardless of age (Table; Ludwig et al, Leuk Lymphoma. 2017;58:2501-2504). Mature overall survival (OS) data has recently been reported from ENDEAVOR and demonstrated that Kd56 resulted in statistically and clinically significant improvement in OS compared with Vd in the intention-to-treat (ITT) population (median, 47.6 months vs 40.0 months; hazard ratio [HR], 0.791; 95% confidence interval ...
I have often said , and everyone is probably tired of hearing that a multiple myeloma qualified professional and a well-informed patient can extend your life expectancy. If you listen to Paula multiple myeloma life expectancy, has followed this formula to the letter. He had a first opinion , then a second opinion, and then a third opinion. He contacted the International Monetary Fund (International Myeloma Foundation ) multiple myeloma life expectancy, became a member of the group, and a leader of the group. He chose a great doctor and a treatment of myeloma. His doctor was none other than David S. Siegel, MD , Ph.D., director of the Division of Multiple Myeloma at John There Cancer Center, Hackensack University Medical Center. Before that , he spent years in the center MSN and worked hand in hand with Dr. Bart Brogue . In 1999 , MSN was and is considered one of the best centers in the world myeloma . So Paula has chosen , and he needed it multiple myeloma life expectancy. He discovered that he ...
Data from two phase I/II clinical trials evaluating ixazomib (Ninlaro) in patients with newly diagnosed multiple myeloma was presented at the 2017 European Hematology Association (EHA) Annual Meeting (Abstracts S408, S780). Both studies evaluated ixazomib plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed patients with multiple myeloma who did not undergo stem cell transplant, followed by maintenance with single-agent ixazomib. Ixazomib is currently not approved for the treatment of newly diagnosed multiple myeloma or in the maintenance setting.. Despite recent progress, multiple myeloma remains a rare, devastating, and incurable hematologic cancer.… These phase I/II data demonstrate the potential use of ixazomib in combination with lenalidomide/dexamethasone in newly diagnosed multiple myeloma and as a single-agent maintenance therapy, which resulted in patients achieving deepening responses with continual use of the treatment. Ixazomibs efficacy and safety profile-coupled ...
TY - JOUR. T1 - A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. AU - Noonan, Kimberly. AU - Marchionni, Luigi. AU - Anderson, Judy. AU - Pardoll, Drew. AU - Roodman, G. David. AU - Borrello, Ivan. PY - 2010/11/4. Y1 - 2010/11/4. N2 - Osteoclast (OC)-mediated lytic bone disease remains a cause of major morbidity in multiple myeloma. Here we demonstrate the critical role of interleukin-17-producing marrow infiltrating lymphocytes (MILs) in OC activation and development of bone lesions in myeloma patients. Unlike MILs from normal bone marrow, myeloma MILs possess few regulatory T cells (Tregs) and demonstrate an interleukin-17 phenotype that enhances OC activation. In univariate analyses of factors mediating bone destruction, levels of cytokines that selectively induce and maintain the Th17 phenotype tightly correlated with the extent of bone disease in myeloma. In contrast, MILs activated under conditions that skew toward a Th1 phenotype ...
Multiple myeloma (MM), a plasma cell dyscrasia, is the most common primary malignancy of the bone marrow.The etiology of myeloma is largely unknown, although genetic predisposition and environmental factors have been speculated. MM arises from malignant plasma cells that clonally expand and accumulate in the bone marrow. These clonal plasma cells produce high levels of monoclonal immunoglobulins. Plasma cell dyscrasias are classified as monoclonal gammopathy of undetermined significance, solitary plasmacytoma, smoldering myeloma, active myeloma, extra-skeletal myeloma, or plasma cell leukemia.. In 2015 an estimated 26,850 adults (14,090 men and 12,760 women) in the United States will be diagnosed with multiple myeloma. It is estimated that 11,240 deaths (6,240 men and 5,000 women) from this disease will occur this year.. In recent years, new and more effective drugs have become available for the treatment of MM. Such drugs have been evaluated together and in combination with older agents, ...
Title:Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis. VOLUME: 14 ISSUE: 4. Author(s):J. Abdi, J. Garssen and F. Redegeld. Affiliation:Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.. Keywords:Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.. Abstract:Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may ...
The introduction of three new drugs for multiple myeloma - Velcade® (bortezomib), Revlimid® (lenalidomide), and Thalomid® (thalidomide) - has improved outcomes among patients with newly-diagnosed multiple myeloma as well as patients with relapsed or refractory multiple myeloma.. Velcade® (bortezomib): Velcade is a targeted therapy that inhibits the activities of a group of proteins, called proteasomes. These proteins are found in virtually all cells, but are particularly important for allowing myeloma cancer cells to survive and grow. By inhibiting the proteasomes, Velcade kills cancer cells and reduced overall cancer growth.. Important support for the use of Velcade in the treatment of relapsed multiple myeloma came from a phase III clinical trial known as the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial. The study enrolled more than 600 patients with relapsed multiple myeloma. Half the patients were treated with Velcade and half were treated with high-dose ...
End stage multiple myeloma is the final stage of advanced multiple myeloma. According to MedlinePlus, the symptoms of end stage multiple myeloma include vomiting, nausea, urination problems, numbness...
Results The most common sites for extramedullary disease at diagnosis were skin and soft tissue whereas liver involvement was the striking feature in extramedullary disease at disease relapse or progression. Regardless of therapy, extramedullary disease was associated with shorter progression-free and overall survival, as well as the presence of anemia, thrombocytopenia, elevated serum lactate dehydrogenase, cytogenetic abnormalities, and high-risk features in 70-and 80-gene risk models in univariate analysis. Multivariate analysis with logistic regression revealed that this disease feature was more prevalent in patients with an elevated centrosome index, as determined by gene expression profiling, as well as in myeloma molecular subtypes that are more prone to relapse. These include the MF subtype (also called the MAF subtype, associated with over-expression of the MAF gene seen with chromosome translocation 14;16 or 14;20) and the PR subtype (also called the Proliferation subtype, ...
Bone complications: In 70% of multiple myeloma cases, the bones develop multiple holes, which explains why the disease is referred to as multiple myeloma. The holes are referred to as osteolytic lesions, which cause the bones to be fragile and subject to fractures. Osteolytic lesions are caused by the rapid growth of myeloma cells, which push aside normal bone-forming cells, preventing them from repairing general wear and tear of the bones. Under normal circumstances, cells called osteoclasts destroy dead and dying bone. Multiple myeloma causes the secretion of osteoclast-activating factor, a substance that stimulates osteoclasts.. Multiple myeloma involving the bone can cause pain, fracture and other significant problems for patients. Management of bone involvement is an integral part of the overall treatment strategy for multiple myeloma. The first objective of treatment of bone complications is to prevent new bone disease from developing or progression from existing bone lesions to ...
This article was originally published by Cancer Health New drugs to treat multiple myeloma are producing better results for patients, with fewer side effects.. For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results in clinical trials.. The drugs are the fruit of years of research into improving treatment for multiple myeloma, a cancer of white blood cells known as plasma cells in the bone marrow. Many of the new agents are biologically derived - made from substances such as proteins and antibodies found in living things - and target biological mechanisms in a very specific, targeted fashion. Dana-Farber researchers have played a key role in these efforts.. These are each powerful examples of how ...
Despite recent advances in the treatment of multiple myeloma, the disease constantly relapses and is still considered as incurable. The current knowledge about the biological mechanisms underlying resistance to the different class of drugs in multiple myeloma remains poor. The primary objective of the MYRACLE (Myeloma Resistance And Clonal Evolution) cohort, a multicenter prospective cohort of patients with multiple myeloma, is to address this limitation. We here describe the study background, design and methods used for this cohort. All patients (| 18 year old) diagnosed with de novo or relapsed multiple myeloma and treated in two hematology department from west of France are included in the MYRACLE cohort. Patients provide a signed informed to be included in the study. All subjects are followed until refusal to participate in the study or death. The MYRACLE cohort prospectively collects data on socio-economic status, medical status, imaging, prognosis factors, MM therapies and associated events
MM patients develop chemoresistance, and increasing the concentrations of cytotoxic drugs fails to significantly improve the therapeutic response. One hypothesis for the development of chemoresistance is related to acquired resistance of the tumor cells to apoptosis (34) , allowing tumors to withstand high levels of chemotherapy. Tumor cells that are resistant to apoptosis also exhibit increased proliferative capacity. Wang et al. (35) reported that activation of NF-κB in response to chemotherapy is a principal mechanism of tumor chemoresistance. Inhibition of such inducible NF-κB activation enhances apoptosis. Increased activity of NF-κB proteins has been reported in solid tumors resistant to chemotherapy (36) . In this report, we found that the activity of NF-κB was elevated in MM tumor cells. The activity of NF-κB appeared to be higher in chemoresistant MM cell lines compared with chemosensitive ones, although the difference was not always consistent between chemosensitive versus ...
The proteasome inhibitor bortezomib has a striking clinical benefit in patients with multiple myeloma. It is unknown whether the bone marrow microenvironment directly contributes to the dramatic response of myeloma cells to proteasome inhibition in vivo. We have used the well-characterized 5TGM1 murine model of myeloma to investigate myeloma growth within bone and response to the proteasome inhibitor bortezomib in vivo. Myeloma cells freshly isolated from the bone marrow of myeloma-bearing mice were found to have an increase in proteasome activity and an enhanced response to in vitro proteasome inhibition, as compared with pre-inoculation myeloma cells. Treatment of myeloma-bearing mice with bortezomib resulted in a greater reduction in tumor burden when the myeloma cells were located within the bone marrow when compared with extra-osseous sites. Our results demonstrate that myeloma cells exhibit an increase in proteasome activity and an enhanced response to bortezomib treatment when located within the
Multiple myeloma is a hematologic malignancy associated with the development of a destructive osteolytic bone disease. Mathematical models are developed for normal bone remodeling and for the dysregulated bone remodeling that occurs in myeloma bone disease. The models examine the critical signaling between osteoclasts (bone resorption) and osteoblasts (bone formation). The interactions of osteoclasts and osteoblasts are modeled as a system of differential equations for these cell populations, which exhibit stable oscillations in the normal case and unstable oscillations in the myeloma case. In the case of untreated myeloma, osteoclasts increase and osteoblasts decrease, with net bone loss as the tumor grows. The therapeutic effects of targeting both myeloma cells and cells of the bone marrow microenvironment on these dynamics are examined. The current model accurately reflects myeloma bone disease and illustrates how treatment approaches may be investigated using such computational approaches. This
TY - JOUR. T1 - Smoldering multiple myeloma risk factors for progression. T2 - a Danish population-based cohort study. AU - Sørrig, Rasmus. AU - Klausen, Tobias W. AU - Salomo, Morten. AU - Vangsted, Annette J. AU - Østergaard, Brian. AU - Gregersen, Henrik. AU - Frølund, Ulf Christian. AU - Andersen, Niels F. AU - Helleberg, Carsten. AU - Andersen, Kristian T. AU - Pedersen, Robert S. AU - Pedersen, Per. AU - Abildgaard, Niels. AU - Gimsing, Peter. AU - Danish Myeloma Study Group. N1 - This article is protected by copyright. All rights reserved.. PY - 2015/12/29. Y1 - 2015/12/29. N2 - Several risk scores for disease progression in Smoldering Multiple Myeloma (SMM) patients have been proposed, however, all have been developed using single center registries. To examine risk factors for time to progression (TTP) to Multiple Myeloma (MM) for SMM we analyzed a nationwide population-based cohort of 321 newly diagnosed SMM patients registered within the Danish Multiple Myeloma Registry between 2005 ...
Multiple myeloma is a cancer of the plasma cells. People with the condition have an increase of abnormal plasma cells (myeloma cells) in their bone marrow, monoclonal protein in their blood and, often, osteolytic bone lesions. As the disease progresses, symptoms of anemia, fatigue, weakness, fractures, bone pain, increased blood calcium, kidney problems, recurrent infections and bleeding are common. The median survival rate is three to four years. The American Cancer Society estimates 20,000 people are diagnosed with multiple myeloma in the U.S. each year.. People with MGUS do not have symptoms associated with multiple myeloma. The disorder is diagnosed by laboratory tests that indicate an increase in M proteins in the blood and elevated bone marrow plasma cells.. I recognized the importance of a having a laboratory that could identify the type of protein and be able to distinguish monoclonal from polyclonal proteins, says Dr. Kyle. I visited the National Institutes of Health and Columbia ...
Earn CME: https://naccme.com/program/7312In this presentation from the Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment? symposium, Dr. C. Ola Landgren argues that MRS is new primary goal for multiple myeloma treatment.© 2018 Imedex, an HMP Company - Multiple Myeloma
Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.
Current criteria for differential diagnosis of multiple myeloma (MM), Monoclonal gammopathy of undetermined significance (MGUS), and smoldering multiple myeloma (SMM) are included in the 2003 guidelines by the International Myeloma Working Group (IMWG). An updated version was then published in 2014, highlighting the importance of serum free light chain (sFLC) detection, as well as the κ/λ ratio as excellent indicators of clonality. At present, two commercial assays for sFLC quantification are available: the Freelite™ assay and the N-Latex assay. The first was developed by The Binding Site based on a mixture of polyclonal antibodies directed against a variety of FLC epitopes. It may be run on a wide range of nephelometers, as well as on turbidimeters. The second method was developed by Siemens and runs exclusively on Siemens instruments. It employs a probe mixture of mouse monoclonal antibodies. The aim of our study was to evaluate sFLC measurement and calculated κ/λ ratio in 85 patients with
Bone destruction is a hallmark of myeloma and affects 80% of patients. Myeloma cells promote bone destruction by activating osteoclasts. In investigating the underlying mechanism, we found that C-reactive protein (CRP), a protein secreted in increased amounts by hepatocytes in response to myeloma-derived cytokines, activated myeloma cells to promote osteoclastogenesis and bone destruction in vivo. In mice bearing human bone grafts and injected with multiple myeloma cells, CRP bound to surface CD32 (also known as FcγRII) on myeloma cells, which activated a pathway mediated by the kinase p38 MAPK and the transcription factor Twist that enhanced the cells secretion of osteolytic cytokines. Furthermore, analysis of clinical samples from newly diagnosed myeloma patients revealed a positive correlation between the amount of serum CRP and the number of osteolytic bone lesions. These findings establish a mechanism by which myeloma cells are activated to promote bone destruction and suggest that CRP ...
Source: Myeloma Research News. People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program.. This program, also known as a named patient program, allows patients and doctors in countries where a medicine is not yet approved or available access to them, provided the medicine is approved in one other country.. Karyopharm Therapeutics, the developer of Xpovio, partnered with Clinigen to open such a program. Under the agreement, Clinigen will distribute and facilitate access to Xpovio in 49 countries across Central and South America, Africa, Asia, and Europe, it announced in a press release.. The therapy will be exclusively available to patients with either multiple myeloma or DLBCL, for whom Xpovio has been approved in the U.S.. Physicians can obtain the details of Xpovios named patient program by contacting Clinigens customer service team by phone (+44-1932-824-123, or ...
Multiple Myeloma (90) Multiple Myeloma Awareness (36) Bone Marrow Transplant (28) Michigan Football (27) Dominate (25) Myeloma Mondays (24) Stem Cell Transplant (24) Multiple Myeloma Survivor Stories (19) Chemo (15) M-Protein (15) Dr. J (14) MM (12) Dexamethasone (11) BMT (10) Ocean (9) UMHS (9) domiNATION (9) Cancer Kicker (8) Hope (8) IgG (8) M Spike (8) MM Awareness (8) Revlimid (8) Story Time (8) Velcade (8) Cancer Kicker Foundation (7) Chemotherapy (7) Dominate Gear (7) M-Spike (7) Ruby (7) Young with Myeloma (7) Dominate Life (6) Multiple Myeloma Bracelets (6) Thankful Thursdays (6) Cancer Kicker Bracelets (5) Complete Response (5) Dominate Myeloma (5) Doxil (5) Iris (5) Michigan Faithful (5) Phil and Cassie Plus Cancer Show (5) RVDD (5) SCT (5) UAMS (5) Big House Big Heart run (4) Bone Marrow Biopsy (4) CancerKicker (4) Consolidation (4) Constipation (4) Cytoxan (4) ER (4) Infusion Center (4) M Protein (4) MMRF (4) Maintenance Therapy (4) Stem Cell Collection (4) Stomach Lava (4) Survivor ...
The main finding reported here is that IL-6-induced proliferation may be dependent on c-Met signaling in myeloma cells. The potentiating effect of HGF/c-Met on IL-6 signaling could be explained by two mechanisms: (i) IL-6 increased the level of c-Met on the cell surface of myeloma cells making cells more sensitive to HGF; and (ii) IL-6 relied on HGF/c-Met to fully activate the Ras-MAPK pathway possibly through Shp2 activation.. HGF is found in bone marrow plasma of both healthy subjects and myeloma patients (5), and bone marrow stromal cells constitutively produce HGF (34). Moreover, syndecan-1 binds HGF on the surface of myeloma cells (5) bringing HGF in close proximity of its receptor c-Met. Immunohistochemical staining for HGF on bone marrow biopsies revealed that plasma cells from almost all myeloma patients stained positive for HGF (K. W. Wader, unpublished data). In this context, the IL-6-induced increase in c-Met expression as shown here may become vital for HGF sensitivity and growth ...
The treatment of multiple myeloma is focused on treating the underlying disease (the increased number of abnormal plasma cells). Managing the symptoms and other medical problems resulting from the increased numbers of plasma cells and abnormal proteins is equally important.. The following complications of multiple myeloma have specific treatments available:. Bone complications: In 70% of multiple myeloma cases, the bones develop multiple holes, which explains why the disease is referred to as multiple myeloma. The holes are referred to as osteolytic lesions, which cause the bones to be fragile and subject to fractures. Osteolytic lesions are caused by the rapid growth of myeloma cells, which push aside normal bone-forming cells, preventing them from repairing general wear and tear of the bones. Under normal circumstances, cells called osteoclasts destroy dead and dying bone. Multiple myeloma causes the secretion of osteoclast-activating factor, a substance that stimulates ...
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118 ...
An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6-9, 2014, in San Francisco, California.. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the bodys immune system. In the U.S., approximately 70,000 people are living with multiple myeloma and approximately 24,000 new individuals are diagnosed annually. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or urine. Patients with multiple myeloma who have become refractory-or resistant-to the drugs Revlimid® (lenalidomide) and Velcade® (bortezomib) have limited treatment options. There is no standard treatment for these patients and they typically have a poor ...
TY - JOUR. T1 - The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. AU - Bergsagel, P. L.. AU - Masellis Smith, A.. AU - Belch, A. R.. AU - Pilarski, L. M.. PY - 1994/1/1. Y1 - 1994/1/1. N2 - Previous reports have described the phenotypic and functional properties of monotypic late stage B cells in the blood of patients with multiple myeloma and have speculated that these B cells represent a malignant circulating component of myeloma. Here we show that blood B cells have IgH rearrangements identical to those expressed by the bone marrow plasma cells by using Ig Fingerprint and Allele-Specific Oligomer (ASO) polymerase chain reaction (PCR) methods. DNA from purified blood B cells and bone marrow plasma cells taken at the same time, and blood B cells taken at subsequent patient visits was amplified using consensus IgH primers, or ASO primers. In 10/16 patients, a single IgH rearrangement was amplified from the bone marrow plasma ...
IgM multiple myeloma is rare disorder, which has clinical, laboratory and radiological manifestations that are consistent with both multiple myeloma and Waldenstroms macroglobulinaemia. An 83 years Welsh lady presented with clinical and radiological features consistent with spinal cord compression. Further investigations confirmed the diagnosis of IgM multiple myeloma. Following localized radiotherapy and five courses of melphalan and prednisolone, the patient achieved partial remission of her myeloma. Later on, the patient had disease progression in the form of rising serum IgM level and the development of multiple plasmacytomas. She was treated with thalidomide, cyclophosphamide, dexamethasone and radiotherapy, which resulted in the control of her disease for one year. To our knowledge, this is the second case of IgM myeloma presenting with a plasmacytoma and the first case of IgM myeloma presenting with cord compression caused by plasmacytomas. Unlike other types of multiple myeloma IgM myeloma is
Between Nov 8, 2007, and June 9, 2010, 125 patients were enrolled and underwent randomisation. 119 patients comprised the per-protocol population and were randomly assigned to receive either lenalidomide plus dexamethasone (n=57) or observation (n=62). The cutoff date for this update was June 30, 2015. Median follow-up for surviving patients was 75 months (IQR 67-85).. Lenalidomide plus dexamethasone continued to provide a benefit on time to progression compared with observation (median time to progression not reached [95% CI 47 months-not reached] vs 23 months [16-31]; hazard ratio [HR] 0·24 [95% CI 0·14-0·41]; p,0·0001). Progression to multiple myeloma occurred in 53 (86%) of 62 patients in the observation group compared with 22 (39%) of 57 patients in the treatment group. At data cutoff, ten (18%) patients had died in the treatment group and 22 (36%) patients had died in the observation group; median overall survival from the time of study entry had not been reached in either group (95% ...
TY - JOUR. T1 - Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. AU - Landgren, Ola. AU - Hofmann, Jonathan N.. AU - McShane, Charlene. AU - Santo, Loredana. AU - Korde, Neha AU - Hultcrantz, Malin. AU - Mailankody, Sham. AU - Kazandjian, Dickran. AU - Murata, Kazunori. AU - Thoren, Katie. AU - Ramanathan, Lakshmi. AU - Dogan, Ahmet. AU - Rustad, Even. AU - Lu, Sydney X.. AU - Akhlaghi, Theresia. AU - Kristinsson, Sigurdur Y.. AU - Björkholm, Magnus. AU - Devlin, Sean AU - Purdue, Mark P.. AU - Pfeiffer, Ruth M.. AU - Turesson, Ingemar. PY - 2019/7/18. Y1 - 2019/7/18. N2 - Importance Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). Risk models that estimate the risk of progression from MGUS to multiple myeloma use data from a single time point, usually the initial workup. Objective To longitudinally investigate the alterations of serum immune markers with stable ...
Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1-7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-28-10. Nonetheless, it has been reported that levels of anti-SARS-CoV-2 serum antibodies decrease rapidly in the first few months after infection, raising concerns that long-lived BMPCs may not be generated and humoral immunity against SARS-CoV-2 may be short-lived11-13. Here we show that in convalescent individuals who had experienced mild SARS-CoV-2 infections (n = 77), levels of serum anti-SARS-CoV-2 spike protein (S) antibodies declined rapidly in the first 4 months after infection and then more gradually over the following 7 months, remaining detectable at least 11 months after infection. Anti-S antibody titres correlated with the frequency of S-specific plasma cells in bone marrow aspirates from 18 individuals who had recovered from COVID-19 at 7 to 8 months after infection. S
1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-9. doi: 10.1056/NEJMoa054494 16571879. 2. Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478-85. doi: 10.1182/blood-2018-04-839480 30012636. 3. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5 25439696. 4. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-5. doi: 10.1182/blood-2012-07-445304 23047823. 5. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, ...
TY - JOUR. T1 - Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. AU - Genuardi, Maurizio. AU - Palumbo, Antonio. AU - Larocca, Alessandra. AU - Genuardi, Mariella. AU - Kotwica, Katarzyna. AU - Gay, Francesca. AU - Rossi, Davide. AU - Benevolo, Giulia. AU - Magarotto, Valeria. AU - Cavallo, Federica. AU - Bringhen, Sara. AU - Rus, Cecilia. AU - Masini, Luciano. AU - Lacobelli, Massimo. AU - Gaidano, Gianluca. AU - Mitsiades, Constantine. AU - Anderson, Kenneth. AU - Boccadoro, Mario. AU - Richardson, Paul. PY - 2010. Y1 - 2010. N2 - Background Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and ...
The International Myeloma Foundation is dedicated to finding a cure for multiple myeloma through global research, and offers myeloma treatment guidelines and support.
The International Myeloma Foundation is dedicated to finding a cure for multiple myeloma through global research, and offers myeloma treatment guidelines and support.
BACKGROUND: Several observational studies have investigated autoimmune disease and subsequent risk of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Findings have been largely inconsistent and hindered by the rarity and heterogeneity of the autoimmune disorders investigated. A systematic review of the literature was undertaken to evaluate the strength of the evidence linking prior autoimmune disease and risk of MGUS/multiple myeloma. METHODS: A broad search strategy using key terms for MGUS, multiple myeloma, and 50 autoimmune diseases was used to search four electronic databases (PubMed, Medline, Embase, and Web of Science) from inception through November 2011. RESULTS: A total of 52 studies met the inclusion criteria, of which 32 were suitably comparable to perform a meta-analysis. Any autoimmune disorder was associated with an increased risk of both MGUS [n = 760 patients; pooled relative risk (RR) 1.42; 95% confidence interval (CI), 1.14-1.75] and multiple ...
Sequential sera from 45 patients with multiple myeloma (MM) and from 6 patients with solid tumors but normal bone marrows who received cyclophosphamide, 15 mg/kg/day for 4 days, were assayed for their effects on tritiated thymidine (3H-TdR) incorporation by normal bone marrow cells and malignant plasma cells. Pretreatment sera from 23 of the 45 patients with MM inhibited normal marrow cell proliferation relative to the effects of normal sera. Of these 45 sera, 30 inhibited plasma cell proliferation. This humoral inhibition was overcome by the induction of humoral stimulation at a predictable time during chemotherapy. The sera obtained sequentially from patients with MM and patients with normal bone marrows increased 3H-TdR uptake by both cell types by days 12-15 of therapy. Sequential changes in malignant marrow plasma cell 3H-TdR labeling indices paralleled the changes in serum activity, with an increased tumor cell growth fraction occurring at the time of peak serum stimulatory activity. The ...
polyneuropathy (1 grade 3), edema (1 grade 3), and pyrexia (1 grade 1). No anti-AMG 420 antibodies were detected at doses up to 800 μg/d. Six patients had a complete response, 1 each at 6.5, 100, and 200 µg/d, and 3 at 400 µg/d; responses were ongoing for the past 3 months. There also were 2 partial remissions, a partial response at 50 µg/d, and a very good partial response at 800 µg/d. All 3 patients treated at 400 µg/d had an MRD-negative complete response.. Clinical Implications: AMG 420 showed evidence of clinical activity in patients with relapsed or refractory multiple myeloma. No major toxicities were observed up to 400 µg/d, and that is the recommended dose for further investigation; dose-limiting toxicities at 800 µg/d were cytokine-release syndrome and peripheral polyneuropathy. (Also, refer to Abstract 592, which highlights the activity of AMG 701, another anti-BCMA bispecific T-cell engager.4) The bispecific T-cell engager technology has already shown efficacy in leukemia and ...
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. (Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, ...
The International Myeloma Foundation (IMF) is an American non-profit organization serving patients with myeloma, a cancer of plasma cells in the bone marrow. The IMF also provides support and information for family members, caregivers of myeloma patients, physicians and nurses. The organization is dedicated to improving the quality of life for all myeloma patients by focusing on four key areas: research, education, support, and advocacy. Founded in 1990 by Brian Novis, Susie Novis, and Brian G.M. Durie, M.D., IMF is a 501(c)3 resource for both patients and caregivers, offering programs that include educational seminars, a patient hotline, multilingual publications, government advocacy, and a web-based Personal Information Management system for recording care and treatment. The IMF is based in North Hollywood, California, and, according to its 2013 annual report, has a membership of 350,000 people in 140 countries. Its motto is Improving lives - Finding the cure. The IMF was founded in 1990 by ...
FDA has accepted Karyopharm Therapeutics Inc.s supplemental New Drug Application seeking approval for Xpovio-its first-in-class, oral selective inhibitor of nuclear export compound, as a new treatment for patients with multiple myeloma after at least one prior line of therapy. Karyopharm expects a decision from the FDA regarding this sNDA before the end of the first quarter of 2021.. If approved, we believe XPOVIO will become an important new, oral, once-weekly treatment option, used in combination with once-weekly Velcade®, for patients with multiple myeloma after at least one prior line of therapy, Sharon Shacham, founder, president and chief scientific officer of Karyopharm, said in a statement.. Xpovio was previously approved by FDA for treatment of patients with penta-refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma. The company also plans to submit a Marketing Authorization Application to the European Medicines Agency later this year for this same ...
Multiple myeloma is a difficult-to-treat hematologic malignancy, where the MYC oncoprotein often plays a key role by stimulating ribosome production and up-regulating protein translation to satisfy the needs of rapidly proliferating cancer cells. By performing a high-throughput screen, Manier et al. determined that small-molecule rocaglate derivatives are active in multiple myeloma. The authors focused on one lead rocaglate derivative and showed that it reversed the effects of MYC, blocked excessive translation, induced tumor cell apoptosis, and decreased tumor cell proliferation. The treatment was safe and effective in multiple mouse models, suggesting rocaglates as potential therapeutic candidates for multiple myeloma. ...
Carlos Fernandez de Larrea, MD, PhD from the Hospital Clínic de Barcelona, Barcelona, Spain gives an overview of his talk on response assessment in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Dr de Larrea, the response assessment in MM is crucial. It is important to establish whether a patient has achieved complete remission (CR) and to identify patients who are relapsing or progressing after different lines of treatment. Dr de Larrea further discusses the various techniques used to assess response, such as electrophoresis in serum and urine and imaging techniques. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
TY - JOUR. T1 - Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma. T2 - Prognostic factors and unique toxicity profile. AU - Hattori, Yutaka. AU - Okamoto, Shin Ichiro. AU - Shimada, Naoki. AU - Kakimoto, Tsunayuki. AU - Morita, Kunihiko. AU - Tanigawara, Yusuke. AU - Ikeda, Yasuo. PY - 2008/6. Y1 - 2008/6. N2 - We previously reported a pilot study of thalidomide monotherapy for Japanese patients with refractory or relapsed multiple myeloma. In the present work, we have extended this clinical trial to a single-institute phase 2 study with a larger number of patients and longer follow-up time. New information on the optimal dose and prognostic factors as well as the correlation of toxicities with treatment schedule was obtained. Fifteen of 56 (27%) patients achieved a partial response, including three cases with near-complete remission. Most patients suffered toxicities at a dose of 400 mg per day, but there was no clear dose-response ...
Multiple myeloma (plasma cell neoplasm) is a rare type of cancer that results in the uncontrolled production of one type of white blood cell (plasma cell) in the bone marrow. The cancer cells can crowd out normal blood cells, causing a reduction in red blood cells (anemia). The overproduction of plasma cells causes an...
TY - JOUR. T1 - Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. AU - Basak, Grzegorz W.. AU - Jaksic, Ozren. AU - Koristek, Zdenek. AU - Mikala, Gabor. AU - Basic-Kinda, Sandra. AU - Mayer, Jiri. AU - Masszi, Tamas. AU - Giebel, Sebastian. AU - Labar, Boris. AU - Wiktor-Jedrzejczak, Wieslaw. PY - 2011/6/1. Y1 - 2011/6/1. N2 - A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the ...
I dont know about you, but I am fielding more and more questions from multiple myeloma patients and caregivers about where to find financial assistance.Here is a link to a site/organization I havent tried called Patient Advocate Foundation Co-Pay Relief:Patient Advocate Foundations Co-Pay Relief (CPR) for Multiple Myeloma Patients.I have personally been aproved by the. ...
TY - JOUR. T1 - 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients. AU - Fallahi, Babak. AU - Beiki, Davood. AU - Mousavi, Seyed Asadollah. AU - Gholamrezanezhad, Ali. AU - Eftekhari, Mohammad. AU - Fard-Esfahani, Armaghan. AU - Alimoghaddam, Kamran. AU - Mirpour, Sahar. AU - Eskandarian, Alireza. AU - Saghari, Mohsen. PY - 2009/9/1. Y1 - 2009/9/1. N2 - Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because 99Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of 99mTc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12±11.46 years) entered ...
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.. ...
However this time I am more apprehensive of the new MRD test. All the current tests for light chains, lesions, bone marrow biopsy, M spike, etc. have always indicated that I was in CR. The MRD test is a far more sensitive test, and will be able to see if there are any myeloma cells left in my system. So a MRD negative result would confirm that my disease is under control based on the most sensitive tests yet available for multiple myeloma diagnostics. And a positive result would just SUCK. Other diseases use a MRD test to determine if a patients treatment has been successful, and when or if it should be changed. MRD is used for acute lymphoblastic leukemia (ALL), and MRD status is one of the most powerful predictors of disease-free and overall survival for children with ALL. The promise for myeloma is that we are able to use this test in the same manner. The International Myeloma Foundation has developed a program called the Black Swan Initiative intended to use a test for MRD with enough ...
TY - JOUR. T1 - Relapse of multiple myeloma presenting as lower lip numbness. AU - Al-Riyami, Yusra M.. AU - Bakathir, Abdulaziz. AU - Al-Farsi, Khalil. AU - Al-Azri, Faisal. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Multiple myeloma (MM) is an uncommon malignancy characterised by the proliferation of clonal plasma cells. There are few published reports describing the extramedullary presentation of MM manifesting primarily in the head and neck region. In addition, the occurrence of an isolated relapse of MM in these sites is exceedingly rare. We report a 56-year-old female who presented to the Sultan Qaboos University Hospital, Muscat, Oman, in 2010 with sudden-onset numbness of the lower lip. She had a history of MM in remission following chemotherapy and a bone marrow transplant. Clinical and radiographic examinations were indicative of a possible relapse of MM, which was subsequently confirmed by bone marrow aspiration and histopathological evaluation. This unique case highlights the unusual site ...
Background: Deleted in liver cancer-1 (DLC-1) is a tumour suppressor gene that is inactive in liver carcinogenesis. It encodes a ρ-guanosine triphosphatase-activating protein (ρ-GAP) and maps to one of the deleted regions (8p21.3-22). Little is known, however, about the methylation status of the DLC-1 promoter in myeloma cells.. Aim: To identify whether methylation of DLC-1 was associated in pathogenesis of multiple myeloma.. Methods: Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect DLC-1 transcripts in RPMI 8226, U266, OPM-2 and XG-2 cell lines. The methylation status was determined by methylation-specific PCR followed by bisulphite DNA sequencing in these four cell lines and in the bone marrow of 14 patients with multiple myeloma and 4 normal patients. DLC-1 mRNA expression in cells with or without treatment with 5-aza-deoxycytidine (5-aza-CdR) or trichostatin A (TSA) was investigated by real-time RT-PCR.. Results: RPMI 8226 and U266 showed complete methylation and ...
The Role of High Dose Chemotherapy With Autologous Stem Cell Rescue in Multiple Myeloma in the Era of Conventional Cytotoxic Chemotherapy. Before the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), high dose melphalan with ASCT following induction therapy was considered the standard approach for transplant-eligible patients with newly diagnosed MM. The first randomized controlled trial from the Intergroupe Francais du Myelome (IFM90), published in 1996, randomized newly diagnosed MM patients to an older chemotherapy regimen (vincristine/carmustine, cyclophosphamide, prednisone alternating with carmustine, vincristine, adriamycin, prednisone; VMCP/BVAP) for 12 cycles versus 4 to 6 cycles of VMCP/BVAP followed by high dose therapy with autologous bone marrow transplant.1 Those patients randomized to the transplant arm compared with the high dose chemotherapy arm had a superior 5-year event-free survival (EFS) (28% versus 10%, respectively, P = .01) and OS (52% ...
Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study Journal Articles Refereed ...